Abstract
The study aims to give a general idea about the experience of chelating drugs among beta-thalassemia
patients in Morocco. It is a declarative survey. It was done in the therapy center of Morocco. Statistics
were done in the laboratory of biological essays in Kenitra. All economic and pharmacological data
were given by Novartis. Sample size was 108.78% of patients attending the service regularly take
deferiprone as treatment while 8% of them combine deferiprone and deferoxamine. Most of the patients
take treatments regularly. Chelators have reduced mortality. They have induced skin lightening for 26%
of the patients in Rabat. Patients taking deferoxamine experienced injection site reactions. Most of
adverse drug reactions (ADR) due to deferiprone were digestive. The main problem with chelators in
Morocco is lack of accessibility to drugs, that’s why the therapy center of Rabat has worked hard in
collaboration with an Italian project to resolve the problem.
Key words: Deferiprone, deferoxamine, prospective study, adverse effects, socio-economic level, behavior
